Findings

What do systematic reviews say?

104 questions · 105 findings · 15 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 14.3%GRADE not reported 11 · 10.5%Very low 22 · 21%Low 32 · 30.5%Moderate 17 · 16.2%High 8 · 7.6%

Lithium vs carbamazepine

Efficacy: response (continuous) CGI change from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Lithium vs carbamazepine

Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lithium vs carbamazepine

Acceptability: total withdrawals · acute mania

Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.2 [0.02, 1.94]
1 study · 34 participants
Low

Lithium vs carbamazepine

Adverse effects: 1. Sedation · acute mania

Lithium showed no clear difference in adverse event: sedation compared with carbamazepine (low certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.16 [0.01, 3.64]
1 study · 27 participants
Low

Clobazam vs carbamazepine

Time on allocated treatment (retention time) · people with focal or generalized seizures

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs carbamazepine

Retention [ · people with focal or generalized seizures

Clobazam showed no clear difference in retention at 12 months compared with carbamazepine (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.83 [0.61, 1.12]
1 study · 115 participants
Low

Clobazam vs carbamazepine

Seizure freedom · people with focal or generalized seizures

Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).

2 findings from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.85 [0.55, 1.32]
1 study · 43 participants
Low
Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.95 [0.66, 1.36]
1 study · 43 participants
Low

Clobazam vs carbamazepine

50% responder rate · people with focal or generalized seizures

Clobazam showed no clear difference in 50% responder rate compared with carbamazepine (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 1.18 [0.94, 1.48]
1 study · 43 participants
Low

Clobazam vs carbamazepine

Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MDAC + hospital intervention vs SDAC + hospital intervention

Incidence of mortality · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

It is very uncertain whether MDAC + hospital intervention changes incidence of mortality compared with SDAC + hospital intervention (very low certainty).

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
RR 0.59 [0.21, 1.63]
2 studies · 3476 participants
Very low

MDAC + hospital intervention vs SDAC + hospital intervention

Incidence of adverse events · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

MDAC + hospital intervention may leads to higher incidence of adverse events compared with SDAC + hospital intervention (low certainty).

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
Peto OR 3.55 [1.85, 6.79]
2 studies · 3476 participants
Low

MDAC + hospital intervention vs SDAC + hospital intervention

Incidence and severity of symptoms of poisoning: incidence of need for intubation · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

MDAC + hospital intervention showed no clear difference in incidence and severity of symptoms of poisoning: incidence of need… compared with SDAC + hospital intervention (low certainty).

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
RR 1.01 [0.75, 1.38]
2 studies · 3097 participants
Low

MDAC + hospital intervention vs SDAC + hospital intervention

Duration of intubation · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
Very low

MDAC + hospital intervention vs SDAC + hospital intervention

Drug absorption: cardenolide: AUC (µg × L/h) · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

MDAC + hospital intervention vs SDAC + hospital intervention

Hospitalization · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

The review found no eligible studies for this question.

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MDAC + hospital intervention vs SDAC + hospital intervention

Incidence of admissions to the ICU · first aid in patients with acute oral poisoning (carbamazepine, yellow oleander, or combinations of different drugs)

MDAC + hospital intervention may leads to lower incidence of ICU admission compared with SDAC + hospital intervention (low certainty).

1 finding from 1 review

First aid interventions by laypeople for acute oral poisoning 2018 · Cochrane Headline outcomes only
RR 0.31 [0.12, 0.83]
1 study · 401 participants
Low

Gabapentin vs carbamazepine

Participant‐reported pain relief of 50% or greater · intensive care unit in India

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs carbamazepine

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · intensive care unit in India

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low

Gabapentin vs carbamazepine

Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low

Gabapentin vs carbamazepine

Rescue analgesic consumption · intensive care unit in India

It is very uncertain whether gabapentin changes rescue analgesic consumption compared with carbamazepine (very low certainty).

1 finding from 1 review

Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
24 participants
Very low